background
respiratori
viral
infect
caus
signific
morbid
mortal
immunocompromis
patient
convent
test
routin
avail
institut
limit
number
detect
pathogen
poor
sensit
andor
long
turnaround
time
object
compar
perform
routin
convent
test
direct
fluoresc
antibodi
assay
viral
cultur
custom
array
card
tac
realtim
pcr
method
target
virus
bacteria
fungi
simultan
studi
design
collect
respiratori
sampl
symptomat
immunocompromis
patient
sampl
convent
tac
result
discord
underw
verif
test
result
tac
assay
identifi
viral
pathogen
sampl
convent
test
versu
mcnemar
p
even
tac
result
virus
could
detect
convent
test
exclud
analysi
versu
p
addit
tac
assay
identifi
sampl
nonvir
pathogen
verif
test
confirm
posit
tac
result
sampl
convent
test
neg
two
three
sampl
posit
convent
test
neg
tac
result
confirm
posit
viral
total
pathogen
coinfect
rate
found
respect
conclus
custom
tac
assay
result
significantli
increas
identif
respiratori
virus
studi
provid
practic
reallif
assess
perform
tac
assay
popul
rapid
accur
diagnosi
viral
atyp
pathogen
crucial
appropri
clinic
manag
acut
respiratori
infect
account
estim
acut
morbid
develop
countri
approxim
viral
etiolog
virus
usual
associ
selflimit
upper
respiratori
tract
ill
immunocompet
host
evok
lower
respiratori
tract
infect
lead
bronchiol
pneumonitispneumonia
acut
clinic
laboratori
mani
commerci
well
inhous
develop
assay
exist
nowaday
offer
syndrom
base
approach
detect
respiratori
pathogen
studi
focuss
array
card
tac
thermo
fisher
scientif
life
technolog
carlsbad
ca
microfluid
technolog
base
singleplex
revers
transcript
realtim
pcr
microfluid
card
card
alreadi
commerci
multipl
gene
express
microrna
express
analys
extens
use
cancer
research
infecti
diseas
diagnost
inhous
develop
custommad
tac
assay
exist
date
goal
present
studi
firstli
character
perform
custom
respiratori
tac
assay
patent
number
premarket
version
cambridgebrugg
bronchoalveolar
lavag
bal
nosethroat
swab
nt
sampl
immunocompromis
patient
comparison
standard
convent
test
detect
respiratori
virus
secondli
aim
gain
insight
role
respiratori
virus
atyp
bacteria
opportunist
fungi
etiolog
agent
upper
lower
respiratori
tract
infect
immunocompromis
patient
studi
popul
includ
adult
immunocompromis
patient
symptom
upper
lower
respiratori
tract
infect
underw
test
respiratori
pathogen
univers
hospit
erasm
decemb
april
immunocompromis
statu
defin
presenc
diseas
andor
treatment
known
impair
immun
system
solid
organ
transplant
sot
immunosuppress
therapi
solid
hematolog
malign
chemotherapi
underli
diseas
need
longterm
corticosteroid
therapi
immunosuppress
therapi
patient
infect
hiv
count
also
includ
electron
medic
record
review
retrospect
clinic
detail
use
structur
case
report
form
convent
test
sampl
aliquot
store
c
studi
test
follow
dfa
respiratori
viru
test
perform
includ
bal
nt
sampl
influenza
ia
b
ib
virus
adenoviru
respiratori
syncyti
viru
rsv
argen
verniol
franc
parainfluenza
virus
piv
argen
verniol
franc
light
diagnost
millipor
usa
human
metapneumoviru
hmpv
light
diagnost
millipor
usa
sampl
rapid
viral
cultur
shell
vial
adenoviru
rsv
influenza
ab
perform
addit
convent
viral
cultur
two
supplementari
cell
line
realiz
bal
sampl
nucleic
acid
extract
l
input
sampl
qiasymphoni
qiagen
valencia
ca
use
dsp
viral
pathogen
midi
kit
combin
pathogencomplex
dsp
gener
dnarna
extract
protocol
elut
l
dilut
phocin
distemp
viru
pdv
ad
extract
intern
extract
inhibit
control
patient
sampl
retrospect
test
respiratori
pathogen
custom
tac
respiratori
panel
includ
test
pathogen
show
fig
patient
sampl
l
nucleic
acid
extract
l
taqman
fast
viru
mastermix
thermo
fisher
scientif
life
technolog
carlsbad
ca
mix
ad
tac
sampl
port
revers
transcriptas
realtim
pcr
perform
quantstudio
thermo
fisher
scientif
life
technolog
carlsbad
ca
use
follow
amplif
protocol
c
min
c
cycl
c
follow
c
system
report
cycl
threshold
posit
pcr
assay
whenev
clear
exponenti
amplif
curv
regist
even
one
gene
target
result
consid
posit
specif
pathogen
base
intern
qc
pdv
data
cv
regist
indic
highli
reproduc
method
discord
convent
respiratori
viru
test
tac
assay
result
verifi
use
realtim
pcr
assay
verif
test
also
perform
nonvir
pathogen
detect
tac
assay
nucleic
acid
extract
use
tac
verif
test
assay
descript
execut
laboratori
target
refer
verif
test
shown
tabl
supplement
materi
sampl
consid
posit
specif
respiratori
pathogen
result
convent
test
posit
match
tac
result
sampl
consid
neg
convent
test
tac
test
yield
neg
result
case
convent
test
result
tac
result
discord
result
confirmatori
test
regard
final
result
convent
test
tac
assay
compar
use
exact
twosid
mcnemar
test
calcul
sensit
specif
cppv
cnpv
correspond
exact
binomi
confid
interv
calcul
separ
convent
test
tac
test
statist
analys
perform
use
medcalc
softwar
mariakerk
belgium
one
hundredforti
three
sampl
obtain
immunocompromis
patient
underw
respiratori
pathogen
test
symptom
upper
lower
respiratori
tract
infect
patient
sampl
characterist
shown
tabl
respect
convent
test
identifi
sampl
one
pathogen
among
sampl
tac
assay
identifi
sampl
one
viral
respiratori
pathogen
detail
result
shown
fig
tabl
almost
one
fifth
includ
sampl
posit
ia
viru
posit
rate
higher
nt
sampl
bal
sampl
differ
statist
signific
nt
sampl
viral
distribut
genu
level
follow
ia
cmv
rhinoviru
rsv
coronaviru
frequent
encount
follow
ib
hmpv
adenoviru
parainfluenza
virus
detect
limit
number
sampl
bal
sampl
less
ia
rsv
coronaviru
found
cmv
rhinoviru
ib
human
mpv
adenoviru
piv
detect
bal
sampl
addit
viral
pathogen
tac
assay
identifi
sampl
p
jirovecii
sampl
aspergillu
speci
sampl
b
parapertussi
pneumonia
l
pneumophila
viral
nonvir
pathogen
consid
one
pathogen
detect
sampl
tabl
show
combin
pathogen
ctvalu
identifi
tac
frequent
involv
coinfect
cmv
n
p
jirovecii
n
rhinoviru
n
influenza
viru
n
tac
assay
significantli
like
detect
respiratori
viru
compar
routin
convent
test
dfa
viral
cultur
mcnemar
p
tac
assay
result
virus
could
detect
convent
test
coronaviru
rhinoviru
cmv
nt
sampl
n
convent
test
result
hsv
n
could
detect
tac
test
exclud
analysi
differ
diagnost
perform
tac
assay
comparison
convent
test
still
signific
p
among
sampl
two
techniqu
disagre
viral
pathogen
neg
convent
test
posit
one
viral
pathogen
tac
assay
fifti
confirm
verif
test
convent
test
identifi
pathogen
tac
assay
neg
lung
kidney
lung
heart
kidney
liver
confirm
verif
pcr
tabl
base
result
viral
diseas
consid
present
sampl
absent
sampl
calcul
sensit
specif
cppv
cnpv
tac
assay
convent
test
detect
respiratori
viral
infect
display
tabl
cppv
convent
test
tac
test
significantli
differ
p
cnpv
tac
assay
substanti
greater
routin
convent
test
p
verif
test
also
perform
nonvir
pathogen
detect
tac
assay
sampl
posit
p
jirovecii
confirm
verif
test
confirm
posit
patient
nt
bal
clinic
indic
one
patient
one
nt
first
respiratori
episod
month
later
nt
bal
second
respiratori
episod
one
patient
nt
bal
differ
respiratori
episod
result
aspergillu
speci
n
pneumonia
n
b
parapertussi
n
one
l
pneumophila
twentyon
patient
nt
bal
sampl
collect
episod
respiratori
tract
infect
symptom
patient
nt
bal
neg
viral
pathogen
found
nt
bal
sampl
patient
appli
tac
test
compar
patient
convent
test
two
remain
patient
coupl
nt
bal
sampl
one
posit
influenza
b
viru
bal
sampl
one
coronaviru
sole
nt
data
demonstr
immunocompromis
patient
tac
assay
identifi
significantli
viral
pathogen
bal
nt
sampl
routin
convent
test
even
tac
assay
result
virus
could
detect
convent
test
exclud
analysi
cppv
convent
test
tac
test
significantli
differ
cnpv
tac
assay
substanti
greater
routin
test
two
six
sampl
classifi
fals
posit
tac
one
gene
target
specif
pathogen
posit
like
verif
result
fals
neg
due
lower
analyt
sensit
four
result
classifi
fals
posit
median
threshold
much
higher
virus
detect
tac
assay
sampl
confirm
valid
test
could
suggest
small
amount
viru
present
sampl
lead
falseneg
verif
test
although
nonspecif
amplif
exclud
approxim
h
need
tac
test
card
setup
run
time
exclud
sampl
extract
time
result
similar
dfa
assay
approxim
h
result
rapid
viral
cultur
report
day
incub
convent
viral
cultur
took
week
compar
overal
posit
rate
epidemiolog
respiratori
virus
found
studi
data
literatur
difficult
import
differ
could
partial
explain
patient
popul
specimen
type
period
sampl
collect
decemb
april
flu
epidem
belgium
almost
one
fifth
includ
sampl
posit
influenza
viru
also
wide
array
virus
includ
tac
assay
fact
sampl
collect
symptomat
patient
import
specimen
type
highlight
sever
studi
bal
specimen
diagnost
yield
rang
report
soccal
et
al
evalu
pair
nasopharyng
bal
fluid
specimen
observ
overal
viral
posit
rate
upper
respiratori
tract
specimen
bal
sampl
p
studi
includ
coupl
nt
bal
sampl
patient
found
similar
posit
rate
sampl
type
respect
sampl
consid
posit
rate
higher
nt
sampl
bal
sampl
differ
statist
signific
dual
even
tripl
infect
routin
report
use
multiplex
pcr
account
posit
specimen
present
studi
found
sampl
one
viral
pathogen
sampl
show
coinfect
includ
pathogen
consid
exact
clinic
interpret
multipathogen
screen
result
alway
easi
ctvalu
moder
higher
especi
opportunist
pathogen
like
cmv
p
jirovecii
aspergillu
speci
benign
asymptomat
colon
contamin
suspect
carriag
opportunist
pathogen
like
sampl
tac
assay
found
one
pathogen
nevertheless
low
viral
load
exclud
clinic
diseas
due
viru
tac
format
sever
advantag
multipathogen
molecular
assay
card
complet
custommad
offer
great
flexibl
composit
card
chosen
relat
patient
popul
interest
note
card
use
studi
includ
herpesvirus
vzv
besid
cmv
could
possibl
interest
immunocompromis
patient
popul
anoth
advantag
spatial
separ
reaction
well
allow
assay
easili
chang
without
need
extens
reoptimis
valid
highli
parallel
multiplex
assay
could
aid
rapid
inclus
novel
emerg
pathogen
addit
technolog
use
realtim
pcr
gener
semiquantit
ctvalu
contrast
mani
commerci
multipathogen
assay
offer
qualit
result
tool
decis
adequ
correct
interpret
result
particularli
case
coinfect
moreov
workflow
simpl
easi
cost
per
test
rel
low
comparison
commerci
multipathogen
molecular
assay
howev
small
reaction
volum
l
may
affect
sensit
sinc
equival
sampl
final
reaction
mixtur
per
individu
well
low
pcr
singleplex
format
theoret
one
log
sensit
assay
array
card
format
also
sampl
treat
individu
high
turnov
need
assur
accept
turnaroundtim
tac
card
develop
kodani
et
al
modifi
weinberg
et
al
contain
duplic
well
detect
one
genet
target
pathogen
except
ia
viru
target
present
doubl
howev
due
genom
variabl
singl
target
test
might
lead
falseneg
result
card
use
studi
includ
one
genet
target
sever
pathogen
interest
limit
falseneg
result
also
help
interpret
result
limit
studi
contrast
convent
test
tac
verif
test
perform
retrospect
therefor
qualiti
sampl
could
deterior
due
freezethaw
cycl
tac
verif
test
studi
also
limit
lack
verif
test
sampl
summari
comparison
routin
convent
test
respiratori
virus
tac
assay
detect
viral
pathogen
among
sampl
obtain
immunocompromis
popul
studi
provid
practic
reallif
assess
perform
custom
tac
assay
popul
rapid
accur
diagnosi
viral
pathogen
crucial
appropri
clinic
manag
none
declar
